Distinguished in SRD5A3-CDG

Stephanie Grunewald

UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
Distinguished in SRD5A3-CDG
UCL Queen Square Institute Of Neurology, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Stephanie Grunewald practices in London, United Kingdom. Ms. Grunewald is rated as a Distinguished expert by MediFind in the treatment of SRD5A3-CDG. Her top areas of expertise are Propionic Acidemia, SRD5A3-CDG, Urea Cycle Disorders (UCD), Liver Transplant, and Gastrostomy.

Her clinical research consists of co-authoring 86 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of SRD5A3-CDG.

Gender
Female

Locations

UCL Queen Square Institute Of Neurology, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 2/Phase 3
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
Enrollment Status: Completed
Publish Date: May 18, 2017
View 1 Less Clinical Trial

86 Total Publications

Comment on: "An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom".
Comment on: "An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom".
Journal: Clinical drug investigation
Published: April 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Grunewald's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile